AG·尊龙凯时

News & Trends

• 112023-01

  Two alliances for Biomedicine and high-end medical devices established

• 242022-11

  IND acceptance by NMPA for SAL0119 tablets for the treatment of active ankylosing spondylitis and moderate-to-severe active rheumatoid arthritis

• 102022-11

  The marketing application of SAL0107 for the treatment of primary hypertension was accepted

• 102022-11

  Speeding up the innovation, Salubris moves into the era of RNA drugs

• 242022-10

  Using AI-enabled drug discovery tools, Salubris has partnered with AlphaMol to develop innovative drugs for obesity

• 172022-10

  Clinical progress of SAL0108 for the treatment of primary hypertension